"Dasatinib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
| Descriptor ID |
D000069439
|
| MeSH Number(s) |
D02.886.675.184 D03.383.129.708.198 D03.383.742.148
|
| Concept/Terms |
Dasatinib- Dasatinib
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825- BMS 354825
- 354825, BMS
- BMS354825
- BMS-354825
|
Below are MeSH descriptors whose meaning is more general than "Dasatinib".
Below are MeSH descriptors whose meaning is more specific than "Dasatinib".
This graph shows the total number of publications written about "Dasatinib" by people in this website by year, and whether "Dasatinib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 10 | 10 |
| 2007 | 0 | 15 | 15 |
| 2008 | 0 | 19 | 19 |
| 2009 | 0 | 39 | 39 |
| 2010 | 0 | 32 | 32 |
| 2011 | 0 | 20 | 20 |
| 2012 | 0 | 17 | 17 |
| 2013 | 0 | 19 | 19 |
| 2014 | 1 | 8 | 9 |
| 2015 | 11 | 6 | 17 |
| 2016 | 9 | 6 | 15 |
| 2017 | 6 | 4 | 10 |
| 2018 | 9 | 6 | 15 |
| 2019 | 5 | 3 | 8 |
| 2020 | 5 | 8 | 13 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 8 | 8 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dasatinib" by people in Profiles.
-
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 Oct 01; 109(10):3251-3260.
-
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352.
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
-
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk. 2024 Jul; 24(7):484-487.
-
Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer. Colloids Surf B Biointerfaces. 2024 Jan; 233:113631.
-
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):149-157.
-
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023 10; 11(10).
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.
-
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748.
-
Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58.